References

  1. Ranexa (ranolazine extended-release tablets) [package insert]. Palo Alto, CA; Mar 2009.
  2. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-316.
  3. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non–ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775-1783.
  4. Data on file, Gilead Sciences, Inc.
  5. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) Trial. J Am Coll Cardiol. 2006;48:566-575.
  6. Morrrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119:2032-2039.
  7. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non–ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36 (MERLIN- TIMI 36) randomized controlled trial. Circulation. 2007;116:1647-1652.
  8. Stone PH, Chaitman B, Koren A, Crager M. Effects of ranolazine as monotherapy and combination therapy on rate pressure product at rest and during exercise: results from the MARISA and CARISA trials. Circulation. 2006;114:II 715. Abstract 3362.
  9. American Heart Association. Heart Disease and Stroke Statistics, 2008 Update. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3000090. Accessed January 29, 2009.
  10. Shoob HD, Croft JB, Labarthe DR. Impact of baby boomers on hospitalizations for coronary heart disease and stroke in the United States. Prev Med. 2007;44:447-451.
  11. US Census Bureau. US population projections. Available at: http://www.census.gov/population/www/projections/natsum-T3.html. Accessed Nov 12, 2008.
  12. Pepine CJ. Angina pectoris in a contemporary population: characteristics and therapeutic implications. TIDES Investigators. Cardiovasc Drugs Ther. 1998 Oct;12 Suppl 3:211-6.
  13. American College of Cardiology and the American Heart Association. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina. http://www.acc.org/qualityandscience/clinical/guidelines/stable/
    IV_treatment.htm#IV_B    . Accessed February 13, 2009.
  14. Morrow DA, Gersh BJ. Chronic coronary artery disease. In: Braunwald E, Libby P, Bonow RO, Mann DL, Zipes DP, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia, PA: Saunders Elsevier; 2008:1353.
  15. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
  16. Marquis P, Fayol C, Joire JE. Clinical validation of a quality of life questionnaire in angina pectoris patients. Eur Heart J. 1995 Nov;16(11):1554-60.
  17. Chestnut LG, Keller LR, Lambert WE, Rowe RD. Measuring heart patients' willingness to pay for changes in angina symptoms. Med Decis Making. 1996 Jan-Mar;16(1):65-77.
Was this page helpful?
Full Prescribing Information

You are now leaving Ranexa.com.

You are now leaving the Ranexa website. Gilead Sciences, Inc. provides these links as a convenience; however, Gilead does not control, review, or endorse third-party websites, and is not responsible for the content of the website you are about to enter.

 

OK OK

Share this page

Fill out the fields below to send this Web page to a colleague.

* required item

Email Address is not a valid email